You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mutated

Showing 1 - 25 of 1,466
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tislelizumab, Bevacizumab, Oxaliplatin Trial in Beijing (Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine)

Recruiting
  • Tislelizumab
  • +7 more
  • Beijing, China
    Lin Yang
Jul 21, 2023

Lung Cancer Stage III Trial (Almonertinib)

Not yet recruiting
  • Lung Cancer Stage III
  • (no location specified)
Aug 8, 2023

Advanced Colorectal Cancer Trial in Hangzhou (Cetuximab Dabrafenib Tislelizumab)

Not yet recruiting
  • Advanced Colorectal Cancer
  • Cetuximab Dabrafenib Tislelizumab
  • Hangzhou, Zhejing, China
    Zhejiang Cancer Institute & Hospital
Jul 19, 2023

Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)

Not yet recruiting
  • Advanced Solid Tumor
  • Non-small Cell Lung Cancers
  • Houston, Texas
    M D Anderson Cancer Center
Nov 15, 2023

Myeloproliferative Disorders, Essential Thrombocythemia, Tumors Trial (JNJ-88549968)

Not yet recruiting
  • Myeloproliferative Disorders
  • +3 more
  • (no location specified)
Nov 21, 2023

Associated Factors, and Clinical Outcomes of Prescribing

Completed
  • BRAF v600 Mutated Metastatic Melanoma
    • East Hanover, New Jersey
      Novartis Pharmaceuticals
    Mar 28, 2023

    Germline BRCA-mutated HER2-negative Breast Cancer Trial in Beijing (Camrelizumab+Fluzoparib)

    Enrolling by invitation
    • Germline BRCA-mutated HER2-negative Breast Cancer
    • Beijing, Beijing, China
      Breast Cancer, Peking University People's Hospital
    Nov 14, 2022

    Anaplastic Thyroid Cancer Trial in Leiden (dabrafenib/trametinib)

    Recruiting
    • Anaplastic Thyroid Cancer
    • Leiden, Zuid-Holland, Netherlands
      Ellen Kapiteijn
    Oct 5, 2023

    NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +2 more
    • Nintedanib, gefitinib, erlotinib, afatinib
    • (no location specified)
    Oct 2, 2023

    NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
    • (no location specified)
    Aug 27, 2023

    Small-cell Lung Cancer Trial in Guangzhou (Serplulimab)

    Recruiting
    • Small-cell Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial Perople's Hospital
    Jul 20, 2023

    Myelofibrosis Trial in France (Clonal architecture determination)

    Not yet recruiting
    • Myelofibrosis
    • Clonal architecture determination
    • Angers, France
    • +6 more
    Jan 24, 2023

    Colorectal Cancer Trial in Changsha (fruquintinib and FOLFIRI)

    Not yet recruiting
    • Colorectal Cancer
    • fruquintinib and FOLFIRI
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Apr 24, 2023

    Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations Trial in Guangzhou (Arsenic trioxide)

    Not yet recruiting
    • Pediatric Cancer
    • +2 more
    • Arsenic trioxide
    • Guangzhou, Guangdong, China
      Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Oct 12, 2023

    KRAS P.G12C, Pancreatic Cancer Trial in Beijing (JAB-21822)

    Not yet recruiting
    • KRAS P.G12C
    • Pancreatic Cancer
    • Beijing, Beijing, China
    • +1 more
    Aug 18, 2023

    Metastatic Cancer, HER2 Gene Mutation Trial in Seoul (Neratinib Maleate)

    Active, not recruiting
    • Metastatic Cancer
    • HER2 Gene Mutation
    • Neratinib Maleate
    • Seoul, Korea, Republic of
      Korea university Guro hospital
    Oct 18, 2023

    NSCLC Trial in Guangzhou (BL-M07D1)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Nov 1, 2023

    TNBC - Triple-Negative Breast Cancer Trial in Nanjing (Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide)

    Recruiting
    • TNBC - Triple-Negative Breast Cancer
    • Nanjing, Jiangsu, China
      JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
    Apr 27, 2023

    EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)

    Recruiting
    • EGFR-Mutated Non-Small-Cell Lung Carcinoma
    • Small Cell/Neuroendocrine
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    NSCLC Trial in Santa Rosa, Ridgewood (Tipifarnib, Osimertinib)

    Recruiting
    • NSCLC
    • Santa Rosa, California
    • +1 more
    Jan 11, 2023

    NSCLC With STK11/LKB1 Mutation Trial in New York (Daratumumab and Hyaluronidase-fihj, Pre-Intervention Medication,

    Not yet recruiting
    • Non-small Cell Lung Cancer With STK11/LKB1 Mutation
    • Daratumumab and Hyaluronidase-fihj
    • +2 more
    • New York, New York
      NYU Langone Health
    Mar 29, 2023

    Non Small Cell Lung Cancer Trial in Hangzhou (Furmonertinib Mesilate Tablets)

    Enrolling by invitation
    • Non Small Cell Lung Cancer
    • Furmonertinib Mesilate Tablets
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, College of Medicine, Zhejiang Uni
    Apr 3, 2023

    Endometrial Cancer Trial (Vaginal brachytherapy, Adjuvant radiotherapy (EBRT +/- brachytherapy), Observation)

    Not yet recruiting
    • Endometrial Cancer
    • Vaginal brachytherapy
    • +2 more
    • (no location specified)
    Nov 29, 2022

    Solid Tumor, KRAS Mutation-Related Tumors Trial in Washington (NEROFE, Doxorubicin)

    Recruiting
    • Solid Tumor
    • KRAS Mutation-Related Tumors
    • Washington, District of Columbia
      Georgetown Lombardi Comprehensive Cancer Center
    Jan 23, 2023

    NSCLC Trial in Beijing (Pyrotinib)

    Recruiting
    • Non-small Cell Lung Cancer
    • Beijing, Beijing, China
      Peking Union Medical College
    Feb 20, 2023